Cargando…
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patien...
Autores principales: | Rolfes, Verena, Idel, Christian, Pries, Ralph, Plötze-Martin, Kirstin, Habermann, Jens, Gemoll, Timo, Bohnet, Sabine, Latz, Eicke, Ribbat-Idel, Julika, Franklin, Bernardo S., Wollenberg, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007942/ https://www.ncbi.nlm.nih.gov/pubmed/29937998 http://dx.doi.org/10.18632/oncotarget.25446 |
Ejemplares similares
-
Increased Abundances of CD16(+) Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4(+) T Cell Disturbances in Oropharyngeal Cancer
por: Idel, Christian, et al.
Publicado: (2022) -
TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
por: von Bernuth, Amelie, et al.
Publicado: (2023) -
EVI1 as a Marker for Lymph Node Metastasis in HNSCC
por: Idel, Christian, et al.
Publicado: (2020) -
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021) -
Elevated LSD1 and SNAIL Expression Indicate Poor Prognosis in Hypopharynx Carcinoma
por: Bottner, Justus, et al.
Publicado: (2022)